Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival.
Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival.
复制标题
DOI:
10.1038/s41467-021-24677-6
复制
发表时间:
2021-07-23
影响因子:
16.6
通讯作者:
Shlien A
中科院分区:
文献类型:
--
作者:
Anderson ND;Babichev Y;Fuligni F;Comitani F;Layeghifard M;Venier RE;Dentro SC;Maheshwari A;Guram S;Wunker C;Thompson JD;Yuki KE;Hou H;Zatzman M;Light N;Bernardini MQ;Wunder JS;Andrulis IL;Ferguson P;Razak ARA;Swallow CJ;Dowling JJ;Al-Awar RS;Marcellus R;Rouzbahman M;Gerstung M;Durocher D;Alexandrov LB;Dickson BC;Gladdy RA;Shlien A
Leiomyosarcomas (LMS) are genetically heterogeneous tumors differentiating along smooth muscle lines. Currently, LMS treatment is not informed by molecular subtyping and is associated with highly variable survival. While disease site continues to dictate clinical management, the contribution of genetic factors to LMS subtype, origins, and timing are unknown. Here we analyze 70 genomes and 130 transcriptomes of LMS, including multiple tumor regions and paired metastases. Molecular profiling highlight the very early origins of LMS. We uncover three specific subtypes of LMS that likely develop from distinct lineages of smooth muscle cells. Of these, dedifferentiated LMS with high immune infiltration and tumors primarily of gynecological origin harbor genomic dystrophin deletions and/or loss of dystrophin expression, acquire the highest burden of genomic mutation, and are associated with worse survival. Homologous recombination defects lead to genome-wide mutational signatures, and a corresponding sensitivity to PARP trappers and other DNA damage response inhibitors, suggesting a promising therapeutic strategy for LMS. Finally, by phylogenetic reconstruction, we present evidence that clones seeding lethal metastases arise decades prior to LMS diagnosis. Heterogeneity in leiomyosarcomas (LMS) makes treatment of the disease challenging. Here the authors analyze LMS heterogeneity and molecular LMS subtypes using genomics and transcriptomics, finding origins in distinct lineages and associations with survival, in addition to the early emergence of metastatic clones.
登录
查看更多内容
影响因子:
8
作者:
Beck, A. H.;Lee, C-H;Witten, D. M.;Gleason, B. C.;Edris, B.;Espinosa, I.;Zhu, S.;Li, R.;Montgomery, K. D.;Marinelli, R. J.;Tibshirani, R.;Hastie, T.;Jablons, D. M.;Rubin, B. P.;Fletcher, C. D.;West, R. B.;van de Rijn, M.
通讯作者:
van de Rijn, M.
影响因子:
64.8
作者:
GTEx Consortium;Laboratory, Data Analysis &Coordinating Center (LDACC)—Analysis Working Group;Statistical Methods groups—Analysis Working Group;Enhancing GTEx (eGTEx) groups;NIH Common Fund;NIH/NCI;NIH/NHGRI;NIH/NIMH;NIH/NIDA;Biospecimen Collection Source Site—NDRI;Biospecimen Collection Source Site—RPCI;Biospecimen Core Resource—VARI;Brain Bank Repository—University of Miami Brain Endowment Bank;Leidos Biomedical—Project Management;ELSI Study;Genome Browser Data Integration &Visualization—EBI;Genome Browser Data Integration &Visualization—UCSC Genomics Institute, University of California Santa Cruz;Lead analysts:;Laboratory, Data Analysis &Coordinating Center (LDACC):;NIH program management:;Biospecimen collection:;Pathology:;eQTL manuscript working group:;Battle A;Brown CD;Engelhardt BE;Montgomery SB
通讯作者:
Montgomery SB
影响因子:
46.9
作者:
Becht, Etienne;McInnes, Leland;Newell, Evan W.
通讯作者:
Newell, Evan W.
DOI:
10.1158/1078-0432.ccr-14-3141
发表时间:
2015-08-01
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
Guo X;Jo VY;Mills AM;Zhu SX;Lee CH;Espinosa I;Nucci MR;Varma S;Forgó E;Hastie T;Anderson S;Ganjoo K;Beck AH;West RB;Fletcher CD;van de Rijn M
通讯作者:
van de Rijn M
影响因子:
5.4
作者:
Dentro, Stefan C.;Wedge, David C.;Van Loo, Peter
通讯作者:
Van Loo, Peter